(NASDAQ: KYMR) Kymera Therapeutics's forecast annual revenue growth rate of 3.01% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.59%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.82%.
Kymera Therapeutics's revenue in 2026 is $39,211,000.On average, 24 Wall Street analysts forecast KYMR's revenue for 2026 to be $3,540,912,270, with the lowest KYMR revenue forecast at $800,095,461, and the highest KYMR revenue forecast at $8,403,451,614. On average, 22 Wall Street analysts forecast KYMR's revenue for 2027 to be $3,830,007,987, with the lowest KYMR revenue forecast at -$1,040,124,100, and the highest KYMR revenue forecast at $8,403,451,614.
In 2028, KYMR is forecast to generate $3,360,319,295 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $8,403,451,614.